Recent advances in delivery systems for anti-HIV1 therapy

References

• Agrawal AK, Gupta CM. Tuftsin-bearing liposomes in treatment of macrophage-based infections. Adv Drug Deliv Rev 2000; 41: 135–146
   PubMed Web of Science ®Google Scholar
• Ahsan F, Rivas IP, Khan MA, Torres Suárez AI. Targeting to macrophages: Role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages. J Control Release 2002; 79: 29–40
   PubMed Web of Science ®Google Scholar
• Akkina R, Banerjea A, Bai J, Anderson J, Li MJ, Rossi J. siRNAs, ribozymes and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS. Anticancer Res 2003; 23: 1997–2005
   PubMed Web of Science ®Google Scholar
• Altmeyer R. Virus attachment and entry offers numerous targets for antiviral therapy. Curr Pharm Design 2004; 10: 3701–3712
   PubMed Web of Science ®Google Scholar
• Álvarez FE, Rogge KJ, Tarrand J, Lichtiger B. Bacterial contamination of cellular blood components. A retrospective review at a large cancer center. Ann Clin Lab Sci 1995; 25: 283–290
   PubMed Web of Science ®Google Scholar
• Amado RG, Mitsuyasu RT, Symonds G, Rosenblatt JD, Zack J, Sun LQ, Miller M, Ely J, Gerlach W. A phase I trial of autologous CD34+ hematopoietic progenitor cells transduced with an anti-HIV ribozyme. Hum Gene Ther 1999; 10: 2255–2270
   PubMed Web of Science ®Google Scholar
• Bai Y, Soda Y, Izawa K, Tanabe T, Kang X, Tojo A, Hoshino H, Miyoshi H, Asano S, Tani K. Effective transduction and stable transgene expression in human blood cells by a third-generation lentiviral vector. Gene Ther 2003; 10: 1446–1457
   PubMed Web of Science ®Google Scholar
• Bauer G, Selander D, Engel B, Carbonaro D, Csik S, Rawlings S, Church J, Kohn DB. Gene therapy for pediatric AIDS. Ann NY Acad Sci 2000; 918: 318–329
   PubMed Web of Science ®Google Scholar
• Bax BE, Bain MD, Talbot PJ, Parker-Williams EJ, Chalmers RA. Survival of human carrier erythrocytes in vivo. Clin Sci (Lond) 1999; 96: 171–178
   PubMed Web of Science ®Google Scholar
• Becker PS. The current status of gene therapy in autologous transplantation. Acta Haematol 2005; 114: 188–197
   PubMed Web of Science ®Google Scholar
• Benatti U, Giovine M, Damonte G, Gasparini A, Scarfi S, De Flora A, Fraternale A, Rossi L, Magnani M. Azidothymidine homodinucleotide-loaded erythrocytes and bioreactors for slow delivery of the antiretroviral drug azidothymidine. Biochem Biophys Res Commun 1996; 220: 20–25
   PubMed Web of Science ®Google Scholar
• Bender AR, von Briesen H, Kreuter J, Duncan IB, Rubsamen-Waigmann H. Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro. Antimicrob Agents Chemother 1996; 40: 1467–1471
   PubMed Web of Science ®Google Scholar
• Bestman-Smith J, Gourde P, Desormeaux A, Tremblay M, Bergeron MG. Sterically stabilized liposomes bearing anti-HLA-DR antibodies for targeting the primary cellular reservoirs of HIV-1. Biochim Biophys Acta 2000; 1468: 161–174
   PubMed Web of Science ®Google Scholar
• Bohjanen PR, Liu Y, Garcia-Blanco MA. Human immunodeficiency virus type I as a target for gene therapy. Front Biosci 1997; 2: 619–634
   Google Scholar
• Bonyhadi ML, Moss K, Voytovich A, Auten J, Kalfoglou C, Plavec I, Forestell S, Su L, Bohnlein E, Kaneshima H. RevM10-expressing T cells derived in vivo from transduced human hematopoietic stem-progenitor cells inhibit human immunodeficiency virus replication. J Virol 1997; 71: 4707–4716
   PubMed Web of Science ®Google Scholar
• Brenner S, Malech HL. Current developments in the design of onco-retrovirus and lentivirus vector systems for hematopoietic cell gene therapy. Biochim Biophys Acta 2003; 1640: 1–24
   PubMed Web of Science ®Google Scholar
• Casimiro DR, Tang A, Chen L, Fu TM, Evans RK, Davies ME, Freed DC, Hurni W, Aste-Amezaga JM, Guan L, Long R, Huang L, Harris V, Nawrocki DK, Mach H, Troutman RD, Isopi LA, Murthy KK, Rice K, Wilson KA, Volkin DB, Emini EA, Shiver JW. Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003; 77: 7663–7668
   PubMed Web of Science ®Google Scholar
• Cavallaro G, Maniscalco L, Caliceti P, Salmaso S, Semenzato A, Giammona G. Glycosylated macromolecular conjugates of antiviral drugs with a polyaspartamide. J Drug Target 2004; 12: 593–605
   PubMed Web of Science ®Google Scholar
• Chan J, O'Donoghue K, de la Fuente J, Roberts IA, Kumar S, Morgan JE, Fisk NM. Human fetal mesenchymal stem cells as vehicles for gene delivery. Stem Cells 2005; 23: 93–102
   PubMed Web of Science ®Google Scholar
• Cockrell AS, Kafri T. HIV-1 vectors: Fulfillment of expectations, further advancements, and still a way to go. Curr HIV Res 2003; 1: 419–439
   PubMed Web of Science ®Google Scholar
• Coupar BE, Purcell DF, Thomson SA, Ramshaw IA, Kent SJ, Boyle DB. Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials. Vaccine 2006; 24(9)1378–1388
   PubMed Web of Science ®Google Scholar
• Cui Z, Mumper RJ. Microparticles and nanoparticles as delivery systems for DNA vaccines. Crit Rev Ther Drug Carrier Syst 2003; 20: 103–137
   PubMed Web of Science ®Google Scholar
• Desormeaux A, Bergeron MG. Lymphoid tissue targeting of anti-HIV drugs using liposomes. Methods Enzymol 2005; 391: 330–351
   PubMed Web of Science ®Google Scholar
• Dinauer N, Lochmann D, Demirhan I, Bouazzaoui A, Zimmer A, Chandra A, Kreuter J, von Briesen H. Intracellular tracking of protamine/antisense oligonucleotide nanoparticles and their inhibitory effect on HIV-1 transactivation. J Control Release 2004; 96: 497–507
   PubMed Web of Science ®Google Scholar
• Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu Rev Immunol 1997; 15: 617–648
   PubMed Web of Science ®Google Scholar
• Dorrell L. Therapeutic immunization strategies for the control of HIV-1. Expert Rev Vaccines 2005; 4: 513–520
   PubMed Web of Science ®Google Scholar
• Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macatney M, Mori J, Rickett G, Smith-Burchnell C, Napier C, Webster R, Armour D, Pirce D, Stammen B, Wood A, Perros M. Maraviroc (UK-427,857), a potent, orally bioavailable and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005; 49: 4721–4732
   PubMed Web of Science ®Google Scholar
• Dropulic B, June CH. Gene-based immunotherapy for human immunodeficiency virus infection and acquired immunodeficiency syndrome. Hum Gene Ther 2006; 17: 577–588
   PubMed Web of Science ®Google Scholar
• Duerr A, Wasserheit JN, Corey L. HIV vaccines: New frontiers in vaccine development. Clin Infect Dis 2006; 43: 500–511
   PubMed Web of Science ®Google Scholar
• Duzgunes N, Simoes S, Konopka K, Rossi JJ, Pedroso de Lima MC. Delivery of novel macromolecular drugs against HIV-1. Expert Opin Biol Ther 2001; 1: 949–970
   PubMed Web of Science ®Google Scholar
• Ebensen T, Paukner S, Link C, Kudela P, de Domenico C, Lubitz W, Guzman CA. Bacterial ghosts are an efficient delivery system for DNA vaccines. J Immunol 2004; 172: 6858–6865
   PubMed Web of Science ®Google Scholar
• El-Aneed A. An overview of current delivery systems in cancer gene therapy. J Control Release 2004; 94: 1–14
   PubMed Web of Science ®Google Scholar
• Excler JL. AIDS vaccine development: Perspectives, challenges & hopes. Indian J Med Res 2005; 121: 568–581
   PubMed Web of Science ®Google Scholar
• Falkner FG, Holzer GW. Vaccinia viral/retroviral chimeric vectors. Curr Gene Ther 2004; 4: 417–426
   PubMed Web of Science ®Google Scholar
• Fanning G, Amado R, Symonds G. Gene therapy for HIV/AIDS: The potential for a new therapeutic regimen. J Gene Med 2003; 5: 645–653
   PubMed Web of Science ®Google Scholar
• Felnerova D, Kudela P, Bizik J, Haslberger A, Hensel A, Saalmuller A, Lubitz W. T cell-specific immune response induced by bacterial ghosts. Med Sci Monit 2004; 10: 362–370
   Web of Science ®Google Scholar
• Franchetti P, Abu Sheikha G, Cappellacci L, Marchetti S, Grifantini M, Balestra E, Perno C, Benatti U, Brandi G, Rossi L, Magnani M. A new acyclic heterodinucleotide active against human immunodeficiency virus and herpes simplex virus. Antiviral Res 2000; 47: 149–158
   PubMed Web of Science ®Google Scholar
• Fraternale A, Casabianca A, Tonelli A, Chiarantini L, Brandi G, Magnani M. New drug combinations for the treatment of murine AIDS and macrophage protection. Eur J Clin Invest 2001; 31: 248–252
   PubMed Web of Science ®Google Scholar
• Fraternale A, Casabianca A, Orlandi C, Cerasi A, Chiarantini L, Brandi G, Magnani M. Macrophage protection by addition of glutathione (GSH)-loaded erythrocytes to AZT and DDI in a murine AIDS model. Antiviral Res 2002; 56: 263–272
   PubMed Web of Science ®Google Scholar
• Fraternale A, Casabianca A, Rossi L, Chiarantini L, Schiavano GF, Palamara AT, Garaci E, Magnani M. Erythrocytes as carriers of reduced glutathione (GSH) in the treatment of retroviral infections. J Antimicrob Chemother 2003; 52: 551–554
   PubMed Web of Science ®Google Scholar
• Fridkin M, Tsubery H, Tzehoval E, Vonsover A, Biondi L, Filira F, Rocchi R. Tuftsin-AZT conjugate: Potential macrophage targeting for AIDS therapy. J Pept Sci 2005; 11: 37–44
   PubMed Web of Science ®Google Scholar
• Fruh K, Simmen K, Luukkonen BGM, Bell YC, Ghazal P. Virogenomics: A novel approach to antiviral drug discovery. Drug Discov Today 2001; 6: 621–627
   PubMed Web of Science ®Google Scholar
• Futaki S. Membrane-permeable arginine-rich peptides and the translocation mechanisms. Adv Drug Deliv Rev 2005; 57: 547–558
   PubMed Web of Science ®Google Scholar
• Gagne JF, Desormeaux A, Perron S, Tremblay MJ, Bergeron MG. Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes. Biochim Biophys Acta 2002; 1558: 198–210
   PubMed Web of Science ®Google Scholar
• Gerber D, Pritsker M, Gunther-Ausborn S, Johnson B, Blumenthal R, Shai Y. Inhibition of HIV-1 envelope glycoprotein-mediated cell fusion by a DL-amino acid-containing fusion peptide: Possible recognition of the fusion complex. J Biol Chem 2004; 279: 48224–48230
   PubMed Web of Science ®Google Scholar
• Gherardi MM, Esteban M. Recombinant poxviruses as mucosal vaccine vectors. J Gen Virol 2005; 86: 2925–2936
   PubMed Web of Science ®Google Scholar
• Giammona G, Cavarallo G, Fontana G, Pitarresi G, Carlisi B. Coupling of the antiviral agent zidovudine to polyaspartamide and in vitro drug release studies. J Control Release 1998; 54: 321–331
   PubMed Web of Science ®Google Scholar
• Giammona G, Cavallaro G, Pitarresi G. Studies of macromolecular prodrugs of zidovudine. Adv Drug Deliv Rev 1999; 39: 153–164
   PubMed Web of Science ®Google Scholar
• Gibbs MA, Sorensen SJ. Hydroxyurea in the treatment of HIV-1. Ann Pharmacother 2000; 34: 89–93
   PubMed Web of Science ®Google Scholar
• Goepfert PA, Horton H, McElrath MJ, Gurunathan S, Ferrari G, Tomaras GD, Montefiori DC, Allen M, Chiu YL, Spearman P, Fuchs JD, Koblin BA, Blattner WA, Frey S, Keefer MC, Baden LR, Corey L. NIAID HIV vaccine trials network. High-dose recombinant canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. J Infect Dis 2005; 192: 1249–1259
   PubMed Web of Science ®Google Scholar
• Gottfredsson M, Bohjanen PR. Human immunodeficiency virus type I as a target for gene therapy. Front Biosci 1997; 2: 619–634
   Google Scholar
• Grimaldi S, Lisi A, Pozzi D, Santoro N. Attempts to use liposomes and RBC ghosts as vectors in drug and antisense therapy of virus infection. Res Virol 1997; 148: 177–180
   PubMedGoogle Scholar
• Gupta B, Levchenko TS, Torchilin VP. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev 2005; 57: 637–651
   PubMed Web of Science ®Google Scholar
• Hamidi M, Tajerzadeh H. Carrier erythrocytes: An overview. Drug Deliv 2003; 10: 9–20
   PubMed Web of Science ®Google Scholar
• Hamm TE, Rekosh D, Hammarskjold ML. Selection and characterization of human immunodeficiency virus type 1 mutants that are resistant to inhibition by the transdominant negative RevM10 protein. J Virol 1999; 73: 5741–5747
   PubMed Web of Science ®Google Scholar
• Hatziioannou T, Perez-Caballero D, Yang A, Cowans S, Bieniasz PD. Retrovitus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. Proc Natl Acad Sci USA 2004; 101: 10774–10779
   PubMed Web of Science ®Google Scholar
• Hu J, Liu H, Wang L. Enhanced delivery of AZT to macrophages via acetylated LDL. J Control Release 2000; 69: 327–335
   PubMed Web of Science ®Google Scholar
• Huang Y, Paxton WA, Wolinski SM, Neumann AU, Zhang L, He T, Kang S, Ceradini D, Jin Z, Yazdanbakhsh, Kursman K, Erickson D, Dragon E, Landau NR, Phair L, Ho DD, Koup RA. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996; 2: 1240–1243
   PubMed Web of Science ®Google Scholar
• Humeau LM, Binder GK, Lu X, Slepushkin V, Merling R, Echeagaray P, Pereira M, Slepushkina T, Barnett S, Dropulic LK, Carroll R, Levine BL, June CH, Dropulic B. Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. Mol Ther 2004; 9: 902–913
   PubMed Web of Science ®Google Scholar
• Hyndman L, Lemoine JL, Huang L, Porteous DJ, Boyd AC, Nan X. HIV-1 Tat protein transduction domain peptide facilitates gene transfer in combination with cationic liposomes. J Control Release 2004; 99: 435–444
   PubMed Web of Science ®Google Scholar
• Ikeda M, Habu Y, Miyano-Kurosaki N, Takaku H. Suppression of HIV-1 replication by a combination of endonucleolytic ribozymes (RNnase p and tRNnase ZL). Nucleosides Nucleotides Nucleic Acids 2006; 25: 427–437
   PubMed Web of Science ®Google Scholar
• Jain RA. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 2000; 21: 2475–2490
   PubMed Web of Science ®Google Scholar
• Jain S, Jain NK. Engineered erythrocytes as a drug delivery system. Indian J Pharm Sci 1997; 59: 275–281
   Google Scholar
• Jason TL, Koropatnick J, Berg RW. Toxicology of antisense therapeutics. Toxicol Appl Pharmacol 2004; 201: 66–83
   PubMed Web of Science ®Google Scholar
• Jin SX, Bi DZ, Wang J, Wang YZ, Hu HG, Deng YH. Pharmacokinetics and tissue distribution of zidovudine in rats following intravenous administration of zidovudine myristate loaded liposomes. Pharmazie 2005; 60: 840–843
   PubMed Web of Science ®Google Scholar
• Johnson PR, Schnepp BC, Connell MJ, Rohne D, Robinson S, Krivulka GR, Lord CI, Zinn R, Montefiori DC, Letvin NL, Clark KR. Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. Virol 2005; 79: 955–965
   Web of Science ®Google Scholar
• Kader A, Davis PJ, Kara M, Liu H. Drug targeting using low density lipoprotein (LDL): Physicochemical factors affecting drug loading into LDL particles. J Control Release 1998; 55: 231–243
   PubMed Web of Science ®Google Scholar
• Kalkut G. Antiretroviral therapy: An update for the non-AIDS specialist. Curr Opin Oncol 2005; 17: 479–484
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Zhanel GG. Concepts on the use of liposomal antimicrobial agents: Applications for aminoglycosides. Clin Infect Dis 1992; 15: 654–667
   PubMed Web of Science ®Google Scholar
• Katragadda A, Bridgman R, Betageri G. Effect of liposome composition and cholesterol on the cellular uptake of stavudine by human monocyte/macrophages. Cell Mol Biol Lett 2000; 5: 483–493
   Web of Science ®Google Scholar
• Keckesova Z, Ylinen LM, Towers GJ. The human and African green monkey TRIMalpha genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc Natl Acad Sci USA 2004; 101: 10780–10785
   PubMed Web of Science ®Google Scholar
• Kitajima I, Hanyu N, Soejima Y, Hirano R, Arahira S, Yamaoka S, Yamada R, Maruyama I, Kaneda Y. Efficient transfer of synthetic ribozymes into cells using hemagglutinating virus of Japan (HVJ)-cationic liposomes. Application for ribozymes that target human t-cell leukemia virus type I tax/rex mRNA. J Biol Chem 1997; 272: 27099–27106
   PubMed Web of Science ®Google Scholar
• Klink D, Schindelhauer D, Laner A, Tucker T, Bebok Z, Schwiebert EM, Boyd AC, Scholte BJ. Gene delivery systems—gene therapy vectors for cystic fibrosis. J Cyst Fibros 2004; 3: 203–212
   PubMedGoogle Scholar
• Kohn DB, Bauer G, Rice CR, Rothschild JC, Carbonaro DA, Valdez P, Hao Q, Zhou C, Bahner I, Kearns K, Brody K, Fox S, Haden E, Wilson K, Salata C, Dolan C, Wetter C, Aguilar-Cordova E, Church J. A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood 1999; 94: 368–371
   PubMed Web of Science ®Google Scholar
• Konopka K, Duzgunes N, Rossi J, Lee NS. Receptor ligand-facilitated cationic liposome delivery of anti-HIV-1 Rev-binding aptamer and ribozyme DNAs. J Drug Target 1998a; 5: 247–259
   PubMed Web of Science ®Google Scholar
• Konopka K, Rossi JJ, Swiderski P, Slepushkin VA, Duzgunes N. Delivery of an anti-HIV-1 ribozyme into HIV-infected cells via cationic liposomes. Biochim Biophys Acta 1998b; 1372: 55–68
   PubMed Web of Science ®Google Scholar
• Kozubek A, Gubernator J, Przeworska E, Stasiuk M. Liposomal drug delivery, a novel approach: PLARosomes. Acta Biochim Pol 2000; 47: 639–649
   PubMed Web of Science ®Google Scholar
• Lambert JS. HIV vaccines in infants and children. Paediatr Drugs 2005; 7(5)267–276
   PubMedGoogle Scholar
• Lamothe B, Joshi S. Current developments and future prospects for HIV gene therapy using interfering RNA-based strategies. Front Biosci 2000; 5: 527–555
   Web of Science ®Google Scholar
• Lanao JM, Sayalero ML. Cells and cell ghosts as drug carriers. Nanoparticles as drug carriers, WP Torchillin. Imperial College Press, London 2006; 329–345
   Google Scholar
• Lee YH, Peng CA. Enhanced retroviral gene delivery in ultrasonic standing wave fields. Gene Ther 2005; 12: 625–633
   PubMed Web of Science ®Google Scholar
• Levy JA. HIV-1: Hitching a ride on erythrocytes. Lancet 2002; 359: 2212–2213
   PubMed Web of Science ®Google Scholar
• Li MJ, Kim J, Li S, Zaia J, Yee JK, Anderson J, Akkina R, Rossi JJ. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol Ther 2005; 12: 900–909
   PubMed Web of Science ®Google Scholar
• Liang WS, Maddukuri A, Teslovich TM, de la Fuente S, Agbottah E, Dadgar S, Kehn K, Hautaniemi S, Pumfery A, Stephan DA, Kashanchi F. Therapeutic targets for HIV-1 infection in the host proteome. Retrovirology 2005; 2: 20–42
   PubMed Web of Science ®Google Scholar
• Liu R, Paxton WA, Wolinsky SM, et al. Homozygous defect in HIV-1 coreceptor account for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86: 367–377
   PubMed Web of Science ®Google Scholar
• Löbenberg R, Araujo L, Krueter J. Body distribution of azidothymidine bound to nanoparticles after oral administration. Eur J Pharm Biopharm 1997; 44: 127–132
   Web of Science ®Google Scholar
• Löbenberg R, Araujo L, von Briesen H, Rodgers E, Kreuter J. Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats. J Control Release 1998; 50: 21–30
   PubMed Web of Science ®Google Scholar
• Lochmann D, Jauk E, Zimmer A. Drug delivery of oligonucleotides by peptides. Eur J Pharm Biopharm 2004; 58: 237–251
   PubMed Web of Science ®Google Scholar
• Luque F, Oya R, Macias D, Saniger L. Gene therapy for HIV-1 infection: Are lethal genes a valuable tool?. Cell Mol Biol 2005; 51: 93–101
   PubMed Web of Science ®Google Scholar
• Magnani M, Rossi L, Brandi G, Schiavano GF, Montroni M, Piedimonte G. Targeting antiretroviral nucleoside analogues in phosphorylated form to macrophages: In vitro and in vivo studies. Proc Natl Acad Sci USA 1992; 89: 6477–6481
   PubMed Web of Science ®Google Scholar
• Magnani M, Rossi L, Fraternale A, Silvotti L, Quintavalla F, Piedimonte G, Matteucci D, Baldinotti F, Bendinelli M. FIV infection of macrophages: In vitro and in vivo inhibition by dideoxycytidine 5′-triphosphate. Vet Immunol Immunopathol 1995; 46: 151–158
   PubMed Web of Science ®Google Scholar
• Magnani M, Rossi L, Fraternale A, Bianchi M, Antonelli A, Crinelli R, Chiarantini L. Erythrocyte-mediated delivery of drugs, peptides and modified oligonucleotides. Gene Ther 2002; 9: 749–751
   PubMed Web of Science ®Google Scholar
• Mankertz J, Matthes E, Rokos K, von Baeyer H, Pauli G, Riedel E. Selective endocytosis of fluorothymidine and azidothymidine coupled to LDL into HIV infected mononuclear cells. Biochim Biophys Acta 1996; 1317: 233–237
   PubMed Web of Science ®Google Scholar
• Mankertz J, Nundel M, von Baeyer H, Riedel E. Low density lipoproteins as drug carriers in the therapy of macrophage-associated diseases. Biochem Biophys Res Commun 1997; 240: 112–115
   PubMed Web of Science ®Google Scholar
• Marchart J, Dropmann G, Lechleitner S, Schlapp T, Wanner G, Szostak MP, Lubitz W. Pasteurella multocida- and pasteurella haemolytica-ghosts: New vaccine candidates. Vaccine 2003; 21: 3988–3997
   PubMed Web of Science ®Google Scholar
• Marusich EI, Parveen Z, Strayer D, Mukhtar M, Dornburg RC, Pomerantz RJ. Spleen necrosis virus-based vector delivery of anti-HIV-1 genes potently protects human hematopoietic cells from HIV-1 infection. Virol 2005; 332: 258–271
   PubMed Web of Science ®Google Scholar
• Mautino MR, Keiser N, Morgan RA. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant. Rev J Virol 2001; 75: 3590–3599
   PubMed Web of Science ®Google Scholar
• Mayr UB, Walcher P, Azimpour C, Riedmann E, Haller C, Lubitz W. Bacterial ghosts as antigen delivery vehicles. Adv Drug Deliv Rev 2005; 57: 1381–1391
   PubMed Web of Science ®Google Scholar
• Millán CG, Marinero ML, Castañeda AZ, Lanao JM. Drug, enzyme and peptide delivery using erythrocytes as carriers. J Control Release 2004; 95: 27–49
   PubMed Web of Science ®Google Scholar
• Miyano-Kurosaki N, Barnor JS, Takeuchi H, Owada T, Nakashima H, Yamamoto N, Matsuzaki T, Shimada F, Takaku H. In vitro and in vivo transport and delivery of phosphorothioate oligonucleotides with cationic liposomes. Antivir Chem Chemother 2004; 15: 93–100
   PubMedGoogle Scholar
• Morel F, Salimi S, Markovits J, Austin TW, Plavec I. Hematologic recovery in mice transplanted with bone marrow stem cells expressing anti-human immunodeficiency virus genes. Hum Gene Ther 1999; 10: 2779–2787
   PubMed Web of Science ®Google Scholar
• Moroziewicz D, Kaufman HL. Gene therapy with poxvirus vectors. Curr Opin Mol Ther 2005; 7: 317–325
   PubMed Web of Science ®Google Scholar
• Moss HA, Tebbs SE, Faroqui MH, Herbst T, Isaac JL, Brown J, Elliott TS. A central venous catheter coated with benzalkonium chloride for the prevention of catheter-related microbial colonization. Eur J Anaesthesiol 2000; 17: 680–687
   PubMed Web of Science ®Google Scholar
• Nielsen MH, Pedersen FS, Kjems J. Molecular strategies to inhibit HIV-1 replication. Retrovirology 2005; 2: 10
   PubMed Web of Science ®Google Scholar
• Noguchi H, Matsumoto S. Protein transduction technology offers a novel therapeutic approach for diabetes. J Hepatobiliary Pancreat Surg 2006; 13: 306–313
   PubMedGoogle Scholar
• O'Doherty U, Swiggard WJ, Malim MH. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J Virol 2000; 74: 10074–10080
   PubMed Web of Science ®Google Scholar
• Oehlke J, Birth P, Klauschenz E, Wiesner B, Beyermann M, Oksche A, Bienert M. Cellular uptake of antisense oligonucleotides after complexing or conjugation with cell-penetrating model peptides. Eur J Biochem 2002; 269: 4025–4032
   PubMedGoogle Scholar
• Oussoren C, Magnani M, Fraternale A, Casabianca A, Chiarantini L, Ingebrigsten R, Underberg WJ, Storm G. Liposomes as carriers of the antiretroviral agent dideoxycytidine-5′-triphosphate. Int J Pharm 1999; 180: 261–270
   PubMed Web of Science ®Google Scholar
• Perno CF, Santoro N, Balestra E, Aquaro S, Cenci A, Lazzarino G, Di Pierro D, Tavazzi B, Balzarini J, Garaci E, Grimaldi S, Calio R. Red blood cells mediated delivery of 9-(2-phosphonylmethoxyethyl)adenine to primary macrophages: Efficiency metabolism and activity against human immunodeficiency virus or herpes simplex virus. Antiviral Res 1997; 33: 153–164
   PubMed Web of Science ®Google Scholar
• Phillips MI. Antisense therapeutics: A promise waiting to be fulfilled. Methods Mol Med 2005; 106: 3–10
   PubMedGoogle Scholar
• Plavec I, Agarwal M, Ho KE, Pineda M, Auten J, Baker J, Matsuzaki H, Escaich S, Bonyhadi M, Bohnlein E. High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: Implication for gene therapy of AIDS. Gene Ther 1997; 4: 128–139
   PubMed Web of Science ®Google Scholar
• Podsakoff GM, Engel BC, Carbonaro DA, Choi C, Smogorzewska EM, Bauer G, Selander D, Csik S, Wilson K, Betts MR, Koup RA, Nabel GJ, Bishop K, King S, Schmidt M, von Kalle C, Church JA, Kohn DB. Selective survival of peripheral blood lymphocytes in children with HIV-1 following delivery of an anti-HIV gene to bone marrow CD34(+) cells. Mol Ther 2005; 12: 77–86
   PubMed Web of Science ®Google Scholar
• Poeschla E, Corbeau P, Wong-Staal F. Development of HIV vectors for anti-HIV gene therapy. Proc Natl Acad Sci USA 1996; 93: 11395–11399
   PubMed Web of Science ®Google Scholar
• Pollard VW, Malim MH. The HIV-1 Rev protein. Annu Rev Microbiol 1998; 52: 491–532
   PubMed Web of Science ®Google Scholar
• Prior S, Gander B, Blarer N, Merkle HP, Subira ML, Irache JM, Gamazo C. In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres. Eur J Pharm Sci 2002; 15: 197–207
   PubMed Web of Science ®Google Scholar
• Putnam DA. Antisense strategies and therapeutic applications. Am J Health Syst Pharm 1996; 53: 151–160
   PubMed Web of Science ®Google Scholar
• Quintana FJ, Gerber D, Kent SC, Cohen IR, Shai Y. HIV-1 fusion peptide targets the TCR and inhibits antigen-specific T cell activation. J Clin Invest 2005; 115: 2149–2158
   PubMed Web of Science ®Google Scholar
• Ramezani A, Ma XZ, Ameli M, Arora A, Joshi S. Assessment of an anti-HIV-1 combination gene therapy strategy using the antisense RNA and multimeric hammerhead ribozymes. Front Biosci 2006; 11: 2940–2948
   PubMed Web of Science ®Google Scholar
• Ranade VV, Hollinger MA. Drug delivery systems2nd ed. CRC Press LLC, Florida 2004
   Google Scholar
• Raulin J. Human immunodeficiency virus and host cell lipids. Interesting pathways in research for a new HIV therapy. Prog Lipid Res 2002; 41: 27–65
   PubMed Web of Science ®Google Scholar
• Reeves JD, Piefer AJ. Emerging drug targets for antiretroviral therapy. Drugs 2005; 65: 1747–1766
   PubMed Web of Science ®Google Scholar
• Remeta DP, Krumbiegel M, Minetti CA, Puri A, Ginsburg A, Blumenthal R. Acid-induced changes in thermal stability and fusion activity of influenza hemagglutinin. Biochemistry 2002; 41: 2044–2054
   PubMed Web of Science ®Google Scholar
• Renneisen K, Leserman L, Matthes E, Schroder HC, Muller WE. Inhibition of expression of human immunodeficiency virus-1 in vitro by antibody-targeted liposomes containing antisense RNA to the env region. J Biol Chem 1990; 265: 16337–16342
   PubMed Web of Science ®Google Scholar
• Rossi L, Serafini S, Cappellacci L, Balestra E, Brandi G, Schiavano GF, Franchetti P, Grifantini M, Perno CF, Magnani M. Erythrocyte-mediated delivery of a new homodinucleotide active against human immunodeficiency virus and herpes simplex virus. J Antimicrob Chemother 2001; 47: 819–827
   PubMed Web of Science ®Google Scholar
• Rossi L, Serafini S, Pierige F, Antonelli A, Cerasi A, Fraternale A, Chiarantini L, Magnani M. Erythrocyte-based drug delivery. Expert Opin Drug Deliv 2005; 2: 311–322
   PubMedGoogle Scholar
• Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C, Muyldermans G, Verhofstede C, Burtonboy G, Georges M, Imai T, Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G, Parmentier M. Resistance to HIV-1 infection in caucasian indivisuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382: 668–669
   PubMed Web of Science ®Google Scholar
• Selvam MP, Buck SM, Blay RA, Mayner RE, Mied PA, Epstein JS. Inhibition of HIV replication by immunoliposomal antisense oligonucleotide. Antiviral Res 1996; 33: 11–20
   PubMed Web of Science ®Google Scholar
• Shang LM. Cyclin-dependent kinases as cellular targets for antiviral drugs. J Antimicrob Chemother 2002; 50: 779–792
   PubMed Web of Science ®Google Scholar
• Siapati EK, Bigger BW, Miskin J, Chipchase D, Parsley KL, Mitrophanous K, Themis M, Thrasher AJ, Bonnet D. Comparison of HIV- and EIAV-based vectors on their efficiency in transducing murine and human hematopoietic repopulating cells. Mol Ther 2005; 12: 537–546
   PubMed Web of Science ®Google Scholar
• Slyker JA, Lohman BL, Mbori-Ngacha DA, Reilly M, Wee EG, Dong T, McMichael AJ, Rowland-Jones SL, Hanke T, John-Stewart G. Modified vaccinia Ankara expressing HIVA antigen stimulates HIV-1-specific CD8 T cells in ELISpot assays of HIV-1 exposed infants. Vaccine 2005; 23: 4711–4719
   PubMed Web of Science ®Google Scholar
• Sokolskaja E, Luban J. Cyclophilin, TRIM5, and innate immunity to HIV-1. Curr Opin Microbiol 2006; 9(4)404–408
   PubMed Web of Science ®Google Scholar
• Song E, Lee SK, Dykxhoorn DM, Novina C, Zhang D, Crawford K, Cerny J, Sharp PA, Lieberman J, Manjunath N, Shankar P. Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages. J Virol 2003; 77: 7174–7181
   PubMed Web of Science ®Google Scholar
• Strizki JM, Tremblay C, Xu S, Wojcik L, Wagner N, Gonsiorek W, Hipkin RW, Chou CC, Pugliese-Sivo C, Xiao Y, Tagat JR, Cox K, Pirestley T, Sorota S, Huang W, Hirsch M, Reyes RG, Baroudy BM. Discovery and characterization of vicriviroc (SCH 417690) a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother 2005; 49: 4911–4919
   PubMed Web of Science ®Google Scholar
• Su L, Lee R, Bonyhadi M, Matsuzaki H, Forestell S, Escaich S, Bohnlein E, Kaneshima H. Hematopoietic stem cell-based gene therapy for acquired immunodeficiency syndrome: Efficient transduction and expression of RevM10 in myeloid cells in vivo and in vitro. Blood 1997; 89: 2283–2290
   PubMed Web of Science ®Google Scholar
• Sugai Y, Sugai K, Fuse A. Current status of bacterial contamination of autologous blood for transfusion. Transfus Apheresis Sci 2001; 24: 255–259
   PubMed Web of Science ®Google Scholar
• Szostak MP, Auer T, Lubitz W. Immune response against recombinant bacterial ghosts carrying HIV-1 reverse transcriptase. Vaccine 1993; 93: 419–425
   Google Scholar
• Szostak MP, Hensel A, Eko FO, Klein R, Auer T, Mader H, Haslberger A, Bunka S, Wanner G, Lubitz W. Bacterial ghosts: Non-living candidate vaccines. Biotechnol 1996; 44: 161–170
   Google Scholar
• Tabrizi CA, Walcher P, Mayr UB, Stiedl T, Binder M, McGrath J, Lubitz W. Bacterial ghosts—biological particles as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol 2004; 15: 530–537
   PubMed Web of Science ®Google Scholar
• Tam RC, Lau JY, Hong Z. Mechanisms of action of ribavirin in antiviral therapies. Antivir Chem Chemother 2001; 12: 261–272
   PubMed Web of Science ®Google Scholar
• Tomanin R, Scarpa M. Why do we need new gene therapy viral vectors? Characteristics, limitations and future perspectives of viral vector transduction. Curr Gene Ther 2004; 4: 357–372
   PubMed Web of Science ®Google Scholar
• Tubiana R, Carcelain G, Vray M, Gourlain K, Dalban C, Chermak A, Rabian C, Vittecoq D, Simon A, Bouvet E, El Habib R, Costagliola D, Calvez V, Autran B, Katlama C. Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The vacciter study (ANRS 094). Vaccine 2005; 23: 4292–4301
   PubMed Web of Science ®Google Scholar
• Valbonesi M, Bruni R, Florio G, Zanella A, Bunkens H. Cellular contamination of plasma collected with various apheresis systems. Transfus Apheresis Sci 2001; 24: 91–94
   PubMed Web of Science ®Google Scholar
• Van Griensven J, De Clercq E, Debyser Z. Hematopoietic stem cell-based gene therapy against HIV infection: Promises and caveats. AIDS Rev 2005; 7: 44–55
   PubMed Web of Science ®Google Scholar
• Vaysse L, Burgelin I, Merlio JP, Arveiler B. Improved transfection using epithelial cell line-selected ligands and fusogenic peptides. Biochim Biophys Acta 2000; 1475: 369–376
   PubMed Web of Science ®Google Scholar
• Veres G, Junker U, Baker J, Barske C, Kalfoglou C, Ilves H, Escaich S, Kaneshima H, Bohnlein E. Comparative analyses of intracellularly expressed antisense RNAs as inhibitors of human immunodeficiency virus type 1 replication. J Virol 1998; 72: 1894–1901
   PubMed Web of Science ®Google Scholar
• Vitas AI, Díaz R, Gamazo C. Effect of composition and method of preparation of liposomes on their stability and interaction with murine monocytes infected with Brucella abortus. Antimicrob Agents Chemother 1996; 40: 146–151
   PubMed Web of Science ®Google Scholar
• Vocero-Akbani AM, Heyden NV, Lissy NA, Ratner L, Dowdy SF. Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein. Nat Med 1999; 5: 29–33
   PubMed Web of Science ®Google Scholar
• Von Briesen H, Ramge P, Krueter J. Controlled Release of antiretroviral drugs. AIDS Rev 2000; 2: 31–38
   Google Scholar
• Von Laer D, Hasselmann S, Hasselmann K. Gene therapy for HIV infection: What does it need to make it work?. J Gene Med 2006; 8: 658–667
   PubMed Web of Science ®Google Scholar
• Walcher P, Mayr UB, Azimpour-Tabrizi C, Eko FO, Jechlinger W, Mayrhofer P, Alefantis T, Mujer CV, DelVecchio VG, Lubitz W. Antigen discovery and delivery of subunit vaccines by nonliving bacterial ghost vectors. Expert Rev Vaccines 2004; 3: 681–691
   PubMedGoogle Scholar
• Xin KQ, Jounai N, Someya K, Honma K, Mizuguchi H, Naganawa S, Kitamura K, Hayakawa T, Saha S, Takeshita F, Okuda K, Honda M, Klinman DM, Okuda K. Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV. Gene Ther 2005; 12: 1769–1777
   PubMed Web of Science ®Google Scholar
• Yap MW, Nisole S, Lynch C, Stoye JP. Trim5alpha protein restricts both HIV-1 and murine leukaemia virus. Proc Natl Acad Sci USA 2004; 101: 10786–10791
   PubMed Web of Science ®Google Scholar
• Zala C, Rouleau D, Montaner JS. Role of hydroxyurea in treatment of disease due to human inmunodeficiency virus infection. Clin Infect Dis 2000; 30: 143–150
   Web of Science ®Google Scholar
• Zelphati O, Zon G, Leserman L. Inhibition of HIV-1 replication in cultured cells with antisense oligonucleotides encapsulated in immunoliposomes. Antisense Res Dev 1993; 3: 323–338
   PubMedGoogle Scholar
• Zelphati O, Imbach JL, Signoret N, Zon G, Rayner B, Leserman L. Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms. Nucleic Acids Res 1994; 22: 4307–4314
   PubMed Web of Science ®Google Scholar
• Zheng J, Xie Y, Campbell R, Song J, Massachi S, Razi M, Chiu R, Berenson J, Yang OO, Chen ISY, Pang S. Involvement of claudin-7 in HIV infection of CD4( − ) cells. Retrovirology 2005; 2: 79–90
   PubMed Web of Science ®Google Scholar